Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04627064 · ClinicalTrials.gov registry record · Phase 1
ABEMA Alone or in COMBO With MK-6482
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT04627064 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 11 participants.
The verdict
NCT04627064, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This research study will assess whether abemaciclib alone or in combination with MK-6482 are safe and effective in slowing down the growth of clear cell renal cell carcinoma (ccRCC). The names of the study drugs in this investigational combination are: * Abemaciclib * MK-6482
Interventions
- DRUG Abemaciclib
- DRUG MK-6482
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-12-31 |
| Est. Completion | 2024-08-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04627064
The ClinicalTrials.gov registry entry for NCT04627064 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abemaciclib is the first listed.
NCT04627064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04627064 about?
NCT04627064 is a clinical study titled "ABEMA Alone or in COMBO With MK-6482". This research study will assess whether abemaciclib alone or in combination with MK-6482 are safe and effective in slowing down the growth of clear cell renal cell carcinoma (ccRCC). The names of the study drugs in this investigational combination are: * Abemaciclib * MK-6482
What is the current status of trial NCT04627064?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2020-12-31. Estimated completion is 2024-08-04.
What interventions are being tested in trial NCT04627064?
The interventions under investigation include: Abemaciclib (DRUG), MK-6482 (DRUG).
Who is sponsoring clinical trial NCT04627064?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.